Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron May 11, 2021 9:52am
140 Views
Post# 33172772

RE:RE:RE:Rexall

RE:RE:RE:RexallYes, but you need to factor in Covid revenue.

$3 million last quarter and likely $4-5 million this quarter (Monday May 17) goes a long way to offsetting any financiing needed.  If we didn't have the say the nearly $10 million from Covid so far that would have been 2 more rounds of financing.  What would that have done to the market cap?

The last financing was approx 9 million shares for $7 million.  Without Covid we would have likely given up 15-20 million shares or more.   That's 20-30% of the outstanding and would have had a much larger impact on market cap.






StevenBirch wrote: Or $0.72 anyway. Look I want it to go up as much as the next guy but this is not a covid stock. Covid testing while important is not the future and not where the money is even though it may add some revenue now. This stock is not at this level because we didn't get the Rexall announcement a month ago, it got  halved because of an incoherent Aristotle message.

Some are trying to remain positive but others are either close to or outright pumpers. I say check the ones who attack anyone who even questions the near term outlook for this stock because the market seems to be backing those people right now.


Thisguyiscool wrote: Hitting $1 today




<< Previous
Bullboard Posts
Next >>